10-Q: Invivyd Reports Q1 2026 Financials, Focus on VYD2311 Development

Invivyd, Inc. filed its Q1 2026 10-Q report, detailing a net loss of $41.4 million and continued investment in its VYD2311 COVID-19 program.

Summary

• Invivyd reported a net loss of $41.4 million for the first quarter of 2026, compared to a net loss of $16.3 million in the same period of 2025.
• Total revenue for Q1 2026 was $13.7 million, an increase from $11.3 million in Q1 2025, primarily driven by sales of PEMGARDA.
• Research and development expenses significantly increased to $30.7 million in Q1 2026 from $10.6 million in Q1 2025, largely due to increased investment in the VYD2311 program.
• Selling, general, and administrative expenses rose to $25.1 million in Q1 2026 from $16.8 million in Q1 2025, attributed to increased personnel and professional service costs.
• The company has $184.2 million in cash and cash equivalents as of March 31, 2026, but has concluded there is substantial doubt about its ability to continue as a going concern without additional funding.
• Key development programs include VYD2311 for COVID-19, with Phase 3 trial data expected in Q3 2026, and candidates for RSV (VBY329) and measles (VMS063).

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative filing due to the significant increase in net loss, rising operating expenses, and the explicit statement of substantial doubt about the company's ability to continue as a going concern, despite progress in pipeline development.

Positives

• Product revenue increased by $2.4 million to $13.7 million in Q1 2026 compared to Q1 2025, driven by higher PEMGARDA sales.
• The company received FDA clearance for its Investigational New Drug (IND) application for VYD2311 and aligned on a pathway for potential Biologics License Application (BLA) submission.
• Top-line data from the Phase 3 DECLARATION clinical trial for VYD2311 is anticipated in the third quarter of 2026.
• The company has $184.2 million in cash and cash equivalents as of March 31, 2026, providing some near-term liquidity.
• Fast Track designation was granted by the FDA for VYD2311 for the prevention of COVID-19 in at-risk individuals.

Negatives

• The company reported a net loss of $41.4 million for Q1 2026, a significant increase from $16.3 million in Q1 2025.
• Research and development expenses more than doubled to $30.7 million in Q1 2026, primarily due to increased investment in VYD2311.
• Selling, general, and administrative expenses increased by $8.3 million to $25.1 million in Q1 2026.
• There is substantial doubt about the company's ability to continue as a going concern without additional funding.
• The company has not yet drawn any funds from its $30 million senior secured term loan facility due to unmet financial covenants.

Risks

• The company has concluded there is substantial doubt about its ability to continue as a going concern without additional funding.
• The company may not be able to obtain necessary future financing on acceptable terms, or at all.
• Failure to obtain regulatory authorization or approval for product candidates could adversely affect business prospects.
• Market acceptance and commercialization of products face risks, including competition.
• Reliance on third-party organizations for discovery, manufacturing, and clinical/commercial success poses risks.

Future Outlook

The company expects to continue incurring significant expenses and potential operating losses as it commercializes PEMGARDA and advances its pipeline, including VYD2311, VBY329, and VMS063. Top-line data from the DECLARATION trial for VYD2311 is anticipated in Q3 2026. The company anticipates increased expenses related to R&D, commercialization efforts, and operating as a public company. There is substantial doubt about the company's ability to continue as a going concern without additional funding.

Management Comments

• Invivyd is devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2, the virus that causes COVID-19.
• PEMGARDA is our first mAb to receive regulatory authorization and was designed to exert continuous pharmaceutical activity in the face of viral evolution.
• Combating COVID-19 will require for years to come a variety of prevention and treatment options with demonstrated efficacy and safety.
• We aim to develop mAbs that could be used in prevention or treatment of serious viral infectious diseases, starting with COVID-19 and expanding into other high-need indications, such as respiratory syncytial virus (RSV) and measles.
• We expect to advance VBY329 toward IND readiness in the second half of 2026.
• We have begun IND-enablement and regulatory outreach to support rapid VMS063 development, with the goal of expedited development with target IND readiness in late 2026.

Industry Context

StockSavvy.ai notes that Invivyd's Q1 2026 results reflect the ongoing challenges and significant investment required in the biopharmaceutical sector, particularly in the development of novel antibody therapies for infectious diseases. The substantial increase in R&D spending highlights the company's commitment to advancing its pipeline, especially the VYD2311 program for COVID-19, in a competitive landscape where regulatory approvals and market access are critical.

Comparison to Industry Standards

• The net loss of $41.4 million in Q1 2026 is substantial, but typical for biopharmaceutical companies in the clinical development phase, which often prioritize R&D investment over immediate profitability.
• The significant increase in R&D expenses to $30.7 million is in line with industry trends for companies advancing late-stage clinical trials, such as the Phase 3 DECLARATION trial for VYD2311.
• The company's cash position of $184.2 million, while substantial, is being rapidly deployed into R&D, a common strategy in the sector. However, the 'going concern' note indicates a need for further capital raises, a frequent necessity for biotechs to fund extensive development programs.
• The focus on monoclonal antibodies for viral diseases places Invivyd within a segment that has seen significant innovation and investment, particularly post-pandemic, with companies like Regeneron and Eli Lilly also heavily involved in antibody therapeutics.

Legal Proceedings

• As of March 31, 2026, the company was not a party to any material legal proceedings.

Related Party Transactions

• Amounts due to Adimab under various agreements were $1.2 million as of March 31, 2026.
• Royalties expensed to Adimab were $0.6 million for the three months ended March 31, 2026.
• Tamsin Berry, a board member, is a Limited Partner of Population Health Partners, L.P. (PHP), which received a warrant to purchase common stock.

Stakeholder Impact

• Shareholders face dilution risk due to the company's need for future capital raises and the potential for unfavorable financing terms.
• Employees may be impacted by the company's going concern status and potential need to curtail operations or R&D programs.
• Creditors and suppliers may face increased risk if the company cannot secure sufficient funding to meet its obligations.

Next Steps

• Anticipate top-line data from the Phase 3 DECLARATION clinical trial for VYD2311 in Q3 2026.
• Advance VBY329 toward IND readiness in the second half of 2026.
• Target IND readiness for VMS063 in late 2026.
• Initiate Phase 2 clinical trial for VYD2311 in individuals with Long COVID or COVID vaccine injury mid-2026.
• Continue SARS-CoV-2 variant monitoring and testing.
• Pursue regulatory authorization or approval for product candidates.
• Seek additional funding through various capital sources.

Key Dates

Recommendation

While Invivyd shows promising pipeline development with VYD2311 and other candidates, the significant increase in net loss, rising expenses, and the explicit mention of substantial doubt about its going concern status warrant caution. The company's ability to secure future funding is critical. Investors should hold and monitor progress on clinical trials and financing efforts.

Keywords

Invivyd, 10-Q, Quarterly Report, COVID-19, Monoclonal Antibody, PEMGARDA, VYD2311, Clinical Trials, FDA, Biopharmaceutical, Biologics License Application, Net Loss, Research and Development